611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
As Schools Reopen, Many Students, Staff Live With High-Risk Family MemberCOVID-19 Poses Added Risk for People With Addiction Disorders: StudyGetting a Hip Replacement? Choice of Hospital Can Be CrucialAlmost 90,000 Young American Adults Will Get Cancer This Year: ReportAnother Rapid COVID-19 Test Shows PromiseDetails Emerge on Unexplained Illness in AstraZeneca COVID Vaccine TrialRising Obesity Levels Put Americans at Risk During Pandemic: CDCMore Pets May Be Getting COVID-19 Than RealizedWildfire Smoke Poses Special Threat to People With AsthmaCOVID-19 Prevention Might Translate Into Record Low Flu Rates: CDCFor Stroke Survivors, Timely Rehab Has Been Jeopardized During PandemicCOVID-19 Has Taken a Toll on Organ DonationCOVID Conflicts Are Putting Big Strains on RelationshipsCoronavirus Vaccine Plan for Americans AnnouncedParkinson's Ups the Odds for Dangerous Falls, But Prevention Is KeyPregnant Women With COVID-19 at High Risk for ComplicationsCompanion Drug Might Help Prevent Kidney Complications of LupusAHA News: Making Sense of Cholesterol – the Good, the Bad and the DietaryDo Ordinary Eyeglasses Offer Protection Against COVID-19?Elevated Blood Clotting Factor Linked to Worse COVID-19 OutcomesParkinson's Drug Eyed as Treatment for Severe Macular DegenerationNew Drug Shows Promise in Preventing Severe COVIDSome Psoriasis Meds May Also Help Prevent Heart DiseaseSmall Study Supports Donor Plasma Therapy for Severe COVID-19Probiotic Might Help Ease Children's EczemaDeath From COVID-19 Very Rare for Americans 21 and Under: ReportEven Exercise May Not Ease Pandemic-Linked StressDoctors Should Watch for Punctured Lungs in COVID PatientsCould COVID-19 Someday Become Seasonal, Like Flu?Is Arthritis Pain Relief as Close as Your Spice Rack?Their Jobs May Put Black Americans at Greater COVID Risk'Flattening the Curve' Saves More Lives Than ThoughtFewer Kids May Be Carrying Coronavirus Without Symptoms Than Believed: StudyCOVID-19 Takes Heavy Toll on KidneysPoll Finds Pandemic Surge in Loneliness Among Older AdultsAstraZeneca COVID Vaccine Trial RestartsDonating Plasma Helps Fight Immune DisorderKids at 2 Utah Day Cares Easily Spread COVID to FamiliesCOVID Hits Young Adults Harder Than Thought: StudyAHA News: A Closer Look at COVID-19 and Heart Complications Among AthletesAt One Hospital, ICU Workers' PPE May Have Kept Coronavirus at BayBlood Pressure Meds Can Affect COVID-19 CareStudy Confirms Restaurants, Bars Are COVID Infection HotspotsHow One Hospital Kept COVID Transmissions at Nearly ZeroJust How Reliable Are COVID-19 Tests? Experts Weigh InUntreated High Blood Pressure a Growing Problem Among AmericansWest Coast Wildfires, COVID a Double Whammy to Lung HealthWho's Most Likely to Binge Eat Amid Pandemic?Colleges in 50 States Seeing COVID Cases on CampusEarly Trial Offers New Hope for People With Hemophilia
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Gene Therapy May Be Long-Term Cure for Type of Hemophilia

HealthDay News
by By Dennis Thompson
HealthDay Reporter
Updated: Jan 2nd 2020

new article illustration

THURSDAY, Jan. 2, 2020 (HealthDay News) -- A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, early clinical trial results indicate.

Patients who received the one-time intravenous therapy continue to have a more than 90% decrease in bleeding events two to three years after their initial treatment, researchers reported Jan. 1 in the New England Journal of Medicine.

The therapy fixes a broken gene in liver cells that causes production of flawed factor VIII, a protein that plays a key role in blood clotting.

People with this genetic mutation have hemophilia A, the most common type of this bleeding disorder. Hemophilia A accounts for 8 out of 10 cases of hemophilia, researchers said.

Hemophilia A patients must inject themselves with factor VIII every other day to prevent bleeding, said lead researcher John Pasi, a professor at Barts and The London School of Medicine and Dentistry in England.

"There's been a massive reduction in bleeding in the patients, and none of them any longer need to regularly treat themselves with factor VIII to prevent bleeding," Pasi said of participants in the phase 1/phase 2 clinical trial. "That huge treatment burden of having to give yourself an intravenous injection every other day has gone away."

The therapy uses a virus to carry the DNA sequence for a functional factor VIII gene into liver cells, he said.

"It infects liver cells and transfers into those cells the factor VIII gene," Pasi said. "Liver cells make factor VIII and then secrete it, and it passes into the circulation."

Seven initial participants in the study have a 96% decrease in bleeding events three years out, researchers report. Another six who joined later had a 92% decrease in bleeding by the end of year two.

"At three years, the patients who were treated at a higher dose were expressing functional levels of factor VIII -- somewhat lower than they were at their peak, but they're still at really good levels that are hugely effective in protecting the patients against bleeding," Pasi said.

A phase 3 trial involving more than 130 patients is underway, he said, and therapy manufacturer BioMarin Pharmaceutical has begun the application process with the U.S. Food and Drug Administration.

The most notable side effect is changes in liver enzymes with some patients, but those go away after treatment with steroids, Pasi said.

The treatment will not initially be available for every hemophilia A patient.

Because it involves infecting the liver with a virus, patients with hepatitis or HIV were kept out of the clinical trial, Pasi said. The treatment is only for adults now.

The biggest roadblock for some patients will be whether their bodies have developed an immune reaction to factor VIII, Pasi said.

About a third of patients with severe hemophilia develop antibodies to factor VIII, he said. Half of those cases resolve on their own, and the rest might need to be treated with immune tolerance protocols to get rid of the antibody.

Meg Bradbury, research director at the Hemophilia Federation of America, said the results are "extremely encouraging." But she noted that work needs to continue to find a cure for everyone with a bleeding disorder.

"This therapy and others like it may not be a one-size-fits-all for everyone," Bradbury said. "We still need to think about who is eligible for this particular therapy, who it will be effective for, and how we can help everyone in our community."

The therapy also is not likely to be cheap. Given that it will be a one-time treatment, its pricing will be different from that of a maintenance drug taken regularly, BioMarin representatives said.

They noted that the annual cost of therapy for a hemophilia A patient in the United States is around $500,000.

More information

The Hemophilia Federation of America has more about hemophilia.